




MESOTHELIOMA UK
Supporting People With This Asbestos Cancer



Leah Taylor


Mesothelioma UK CNS Team Leader

Mesothelioma Update


EAG Audit Event Thursday 27th September 2018







National Mesothelioma Audit report 2018



National Mesothelioma Audit

Mesothelioma UK and the Royal College of Physicians

Results from 2014–16



Demographics

153 


organisations
across England and Wales
submitted data that
contributed to this report

7,192 


individual patients
were diagnosed with
mesothelioma during
the audit period







Data completeness



Survival



Treatment




Royal College
of Physicians



MESOTHELIOMA UK

Supporting People With This Asbestos Cancer

Performance



National

Pathological subtype **64%**

Anti cancer treatment **51%**

Chemotherapy (PS 0-1) **59%**

Surgery **4%**

Radiotherapy **22%**

1 year survival **38%**

Northern England

Pathological subtype **74.9%**

Anti cancer treatment **50.4%**


Chemotherapy (PS 0-1) **69.4%**

Surgery **0.8%**



Radiotherapy **20.3%**

1 year survival **37.3%**





Mesothelioma Audit Data 2014-16 Northern England






Regional data by Trust







Data completeness

Performance status (PS) describes a patient's level of functioning in terms of their ability to care for themselves, daily activity and physical ability. It is measured using a 5-point scale which can range from 0 (good function) to 4 (poor function). Stage refers to the extent of the cancer, such as how large the tumour is and whether it has spread. The new British Thoracic Society (BTS) guidelines recommend that all cases of diagnosed MPM are staged using the new IASLC/IMIG TNM 8 clinical staging system.

Trust	PS recorded	Stage recorded
Northern England	73.1%	46.2%
South Tyneside NHS FT	91.4%	8.6%
City Hospitals Sunderland NHS FT	72.3%	23.4%
North Cumbria University Hospitals NHS Trust	56.8%	5.4%
Gateshead Health NHS FT	85.2%	48.1%
The Newcastle Upon Tyne Hospitals NHS FT	74.0%	52.1%
 Northumbria Healthcare NHS FT	64.4%	74.6%
South Tees Hospitals NHS FT	70.1%	35.8%
North Tees and Hartlepool NHS FT	90.3%	71.0%
County Durham and Darlington NHS FT	69.4%	33.9%

 For England, the national average for PS was **68.1%** compared to a standard of **90.0%**, and the national average for stage was **54.0%** compared to a standard of **90.0%**.






Summary of Unadjusted Results

Trust	Cases	PCR ¹	Subtype ²	LCNS ³	Anti-Cancer ⁴	Surgery (radical) ⁵	SACT in PS 0-1 ⁶	Survival ⁷
Northern England	528	83.0%	63.3%	61.2%	50.4%	0.8%	69.4%	37.3%
South Tyneside NHS FT	35	74.3%	37.1%	82.9%	57.1%	8.6%	75.0%	53.1%
City Hospitals Sunderland NHS FT	47	89.4%	85.1%	80.9%	46.8%	0.0%	60.0%	32.6%
North Cumbria University Hospitals NHS Trust	37	78.4%	51.4%	40.5%	54.1%	0.0%	73.3%	41.7%
Gateshead Health NHS FT	27	88.9%	81.5%	66.7%	33.3%	0.0%	60.0%	19.2%
The Newcastle Upon Tyne Hospitals NHS FT	73	91.8%	69.9%	78.1%	57.5%	0.0%	84.8%	47.0%
Northumbria Healthcare NHS FT	118	78.8%	53.4%	78.0%	48.3%	0.0%	59.6%	39.1%
South Tees Hospitals NHS FT	67	85.1%	73.1%	26.9%	55.2%	0.0%	72.7%	30.6%
North Tees and Hartlepool NHS FT	62	75.8%	59.7%	74.2%	38.7%	1.6%	64.0%	24.6%
County Durham and Darlington NHS FT	62	85.5%	64.5%	16.1%	56.5%	0.0%	75.0%	43.1%
England	6642	88.2%	63.3%	52.1%	51.4%	4.5%	58.8%	38.0%


¹ Proportion of all patients with pathological confirmation of mesothelioma :: ² Proportion of all patients whose mesothelioma is subtyped :: ³ Proportion of all patients assessed by a specialist nurse :: ⁴ Proportion of all patients who have anti-cancer treatment (surgery, radiotherapy, systemic treatment) :: ⁵ Proportion of patients who undergo radical surgery :: ⁶ Proportion of patients with with PS 0-1 who have systemic anti-cancer treatment :: ⁷ Proportion of patients alive at 1 year after diagnosis



Recommendations

1. Data completeness for the performance status field should exceed 90%.
2. In accordance with TNM8, clinical teams are encouraged to record clinical TNM staging at multidisciplinary team meetings for MPM patients. Hospital trusts should aim for an overall recording of stage in at least 90% of cases.
3. At least 95% of patients submitted to the audit should be discussed at a mesothelioma multidisciplinary team (MDT) meeting.
4. All MDTs should appoint a 'clinical data lead' with protected time to allow promotion of data quality, governance and quality improvement.
5. Pathological confirmation should be over 95%, and where the proportion of cases of unspecified MPM is above 10%, review of diagnostic procedures and pathological processing is recommended.
6. At least 90% of patients should be seen by a CNS and signposted to MesoUK resources including the mesothelioma CNS helpline if there is not a locally available mesothelioma CNS; at least 80% of patients should have a CNS present at the time of diagnosis.






Recommendations

7. Patients with adequate performance status should be offered active anti-cancer treatment, including palliative chemotherapy. MDTs with chemotherapy rates (in good PS patients) below 60% should perform detailed case note review to ascertain why. High-quality patient information should be available to guide treatment decisions.
8. For patients undergoing surgical treatment, every effort should be made to accurately record the OPCS-4 code of the procedure undertaken.
9. All patients should be offered access to relevant clinical trials even if this requires referral outside of their network.
10. Where survival is below national average, an in-depth local audit is recommended, including analysis of active anti-cancer treatment rates and length of the diagnostic pathway.





Recommendations

11. All patients with peritoneal mesothelioma should be referred for discussion at a mesothelioma MDT and signposted to MesoUK resources; patients of good PS should be considered for treatment with palliative chemotherapy.
12. For patients with peritoneal mesothelioma who have good PS and epithelioid subtype refer to the national peritoneal mesothelioma MDT for consideration of cytoreductive surgery.






Clinical Trials



1st line & maintenance




MARS 2

- All subtypes
- Surgical sites –
 - Barts, Sheffield, Leicester, Cardiff, Glasgow
- Medical sites –
 - South Tyneside, South Tees, Northumbria Q4 2018

ATOMiC

- **Sarcomatoid/Biphasic**
- Chemo + ADI-PEG20 v Chemo + placebo
- Northumbria opening Q4 (2018)
 - Sites – Wansbeck & North Tyneside Hospitals
- Dr Mulvenna - Principal Investigator




Maintenance

NEMO

- All subtypes
- Switch maintenance
Nintedanib v Placebo
after 1st line chemo
- South Tyneside



2nd line




FAK/PD1 – Defactinib & Pembrolizumab

- All subtypes
- Pleural & peritoneal
- **Glasgow/Edinburgh**

VIM – Vinorelbine v ASC

- All subtypes
- Multiple centres – nearest **Sheffield**


3rd line



CONFIRM – Nivolumab v Placebo (2:1)

- All subtypes
- Pleural and Peritoneal
- Northumbria opening Q4 2018
 - North Tyneside & Wansbeck Hospitals
 - Dr Gardiner – Principal Investigator


Radiotherapy



SYSTEMS-2

- Standard v dose escalated RT for pain control
- 20Gy in 5 fractions over 1 week
- 36Gy in 6 fractions over 2 weeks
- All subtypes
- Newcastle – in set up





Coming
soon.....

MESO TRIALS
Supporting People With This Asbestos Cancer


Available on the
App Store

Get it on
Google play

JUICEAPPS



MESOTHELIOMA UK
Supporting People With This Asbestos Cancer




Private Treatment

- Mainly immunotherapy
 - Limited evidence currently to support use in any stage of disease
- Bevacizumab 1st line
 - BTS Guidelines
- Patients may be able to cover cost through compensation claim
- Impact on trial recruitment?



Support Groups



☐ South Tyneside Self Help Group (MKMRF)

- Washington

☐ PRASAG

- Darlington
- Morpeth






Fundraising



£36,000 raised



PRASAG


Paul Readhead Asbestos Support Awareness Group

*...providing support & awareness
for people affected by asbestos
related diseases and their families*



MESOTHELIOMA UK
Supporting People With This Asbestos Cancer

The north east, a small ray of light....?





MESOTHELIOMA UK
Supporting People With This Asbestos Cancer

Thank you

www.mesothelioma.uk.com

✉ leah.taylor@nhct.nhs.uk

☎ 07966489967

✉ info@mesothelioma.uk.com

☎ 0800 169 2409

